Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

By LabMedica International staff writers
Posted on 12 Jun 2026

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate routine workflows. More...

While artificial intelligence (AI)-enabled digital pathology offers scalable, quantitative analysis, adoption remains limited by costly imaging systems and the need for reliable measures of prediction confidence. New findings demonstrate a compact imaging and AI platform that automates HER2 assessment while flagging cases that may need additional review.

University of California, Los Angeles (UCLA) researchers developed an uncertainty-aware computational pathology platform that combines lensfree holographic imaging with deep learning to automate HER2 scoring in breast cancer tissue. The compact lensfree system captures diffraction patterns over a large field of view from immunohistochemically stained samples, then computationally reconstructs the specimen for AI-based analysis. To bolster reliability, the workflow integrates a confidence-aware deep learning framework with Bayesian uncertainty quantification that estimates prediction confidence and flags low-certainty cases for additional review.

In a blinded test set of 412 breast tissue samples, the platform achieved 84.9% accuracy for four-class HER2 scoring and 94.8% accuracy for clinically relevant binary classification. Selectively identifying less-certain predictions yielded an overall error-correction rate of 30.4%, providing an added layer of safety for clinical decision support by mitigating low-confidence outputs. Despite simplified optical hardware, performance was comparable to conventional brightfield microscopy–based digital pathology while enabling high-throughput imaging across a large sample area.

The study is published in BME Frontiers on May 21, 2026. The researchers note that this lensfree imaging–AI paradigm can extend beyond HER2 to other biomarker evaluation tasks and digital pathology applications. By pairing uncertainty-aware AI with compact computational imaging hardware, the approach is presented as a route toward more accessible and trustworthy AI-assisted diagnostics for cancer detection, diagnosis and treatment guidance.

"Reliable uncertainty estimation is a critical component for the safe deployment of AI in health care," said Aydogan Ozcan, Chancellor’s Professor at UCLA and lead author of the study. "By combining computational imaging, deep learning and uncertainty quantification, we aim to create accessible and trustworthy diagnostic technologies that can support pathology workflows in both advanced and resource-limited health care settings." 

Related Links
University of California, Los Angeles


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
AGGRENG-40
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.